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Abstract
Aims/hypothesis The aims of this study were to evaluate sys-
tematically the predictive power of comprehensive metabolo-
mics profiles in predicting the future risk of type 2 diabetes,
and to identify a panel of the most predictive metabolic
markers.
Methods We applied an unbiased systems medicine approach
to mine metabolite combinations that provide added value in
predicting the future incidence of type 2 diabetes beyond
known risk factors. We performed mass spectrometry-based
targeted, as well as global untargeted, metabolomics, measur-
ing a total of 568 metabolites, in a Finnish cohort of 543 non-
diabetic individuals from the Botnia Prospective Study, which
included 146 individuals who progressed to type 2 diabetes by
the end of a 10 year follow-up period. Multivariate logistic
regression was used to assess statistical associations, and
regularised least-squares modelling was used to perform ma-
chine learning-based risk classification and marker selection.
The predictive performance of the machine learning models
and marker panels was evaluated using repeated nested cross-
validation, and replicated in an independent French cohort of
1044 individuals including 231 participants who progressed to
type 2 diabetes during a 9 year follow-up period in the DESIR
(Data from an Epidemiological Study on the Insulin Resistance
Syndrome) study.
Results Nine metabolites were negatively associated (poten-
tially protective) and 25 were positively associated with pro-
gression to type 2 diabetes. Machine learningmodels based on
the entire metabolome predicted progression to type 2 diabetes
(area under the receiver operating characteristic curve,
AUC = 0.77) significantly better than the reference model
based on clinical risk factors alone (AUC = 0.68; DeLong’s
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p = 0.0009). The panel of metabolic markers selected by the
machine learning-based feature selection also significantly
improved the predictive performance over the reference model
(AUC = 0.78; p = 0.00019; integrated discrimination im-
provement, IDI = 66.7%). This approach identified novel pre-
dictive biomarkers, such as α-tocopherol, bradykinin hy-
droxyproline, X-12063 and X-13435, which showed added
value in predicting progression to type 2 diabetes when com-
bined with known biomarkers such as glucose, mannose and
α-hydroxybutyrate and routinely used clinical risk factors.
Conclusions/interpretation This study provides a panel of
novel metabolic markers for future efforts aimed at the pre-
vention of type 2 diabetes.
Keywords Biomarkers . Early prediction . Kallikrein–kinin
system .Machine learning .Metabolomics . Multivariate
models . Prevention . Risk classification
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Type 2 diabetes is a major disease that affects more than 420
million individuals worldwide; if current trends continue, the
number will surpass 700 million individuals by 2025 [1].
Predictive biomarkers are needed to allow physicians to iden-
tify and monitor individuals at high risk for the disease.
Metabolomic profiling of the complete set of small-molecule
metabolites allows for capturing physiological and pathophys-
iological changes in the body [2, 3]. Metabolomics has proved
to be a rich source of markers for diabetes [4–9], and improved
the prediction of type 2 diabetes incidence beyond clinical and
biological markers [10]. For instance, untargeted plasma meta-
bolomics measuring 447 metabolites in a large cohort of wom-
en from the TwinsUK study found metabolites associated with
hyperglycaemia and type 2 diabetes [11], revealing a large set
of potential metabolic markers including amino acids, carbo-
hydrates, lipids, xenobiotics and unknowns, and highlighted an
important role for the catabolism of branched chain amino
acids (BCAAs) in type 2 diabetes. Another untargeted metabo-
lomics study measured more than 4500 metabolites in a pro-
spective cohort of 300 individuals who developed type 2 dia-
betes during 6 years follow-up and 300 matched control partic-
ipants, and identified several metabolic alterations in lipid me-
tabolism and sugars [12]. A recent meta-analysis of 19 prospec-
tive and 27 cross-sectional studies revealed the association of
several metabolites with the incidence of prediabetes (i.e. im-
paired glucose tolerance, impaired fasting glucose, insulin re-
sistance or impaired insulin sensitivity) and type 2 diabetes,
including hexoses, aromatic amino acids, phospholipids and
triacylglycerols, and confirmed the key role of BCAAs and
aromatic amino acids in the prediction of type 2 diabetes [9].
Wang et al measured 61 metabolites and examined whether
multi-metabolite panels could jointly predict the type 2 diabe-
tes risk in 2422 normoglycaemic individuals followed for
12 years in the Framingham Offspring Study [13]. They
showed that BCAAs and aromatic amino acids were signifi-
cantly associated with the future risk of type 2 diabetes, and
that the combination of isoleucine, tyrosine and phenylalanine
predicted the risk. Gall et al used untargeted metabolomics in a
cohort of 399 non-diabetic individuals from the RISC
(Relationship of Insulin Sensitivity to Cardiovascular Risk)
study, and identified α-hydroxybutyrate (α-HB) as an early
biomarker for insulin resistance and glucose intolerance [14].
Using the entire RISC cohort and a long-term observational
cohort of at-risk individuals in the Botnia Prospective Study
(BPS), Ferrannini et al performed targeted profiling of α-HB
and 1-linoleoyl glycerophosphocholine (L-GPC) and showed
that these markers jointly predicted insulin resistance and glu-
cose intolerance [15]. These studies indicate that alterations in
blood metabolite concentrations presage the onset of type 2
diabetes and aid in the identification of at-risk individuals by
adding predictive information over standard clinical markers.
The objectives of the present data-driven study were to
systematically assess the added value of comprehensive meta-
bolomics data in predicting type 2 diabetes risk using machine
learning-based predictive modelling, and to examine whether
an unbiased feature-selection approach could identify novel
metabolic marker combinations that improve the predictive
performance over known biomarkers and clinical risk factors.
We performed serum metabolomics in a prospective, follow-
up study cohort of 543 non-diabetic individuals from the BPS,
146 of whom developed type 2 diabetes during a 10 year
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follow-up period. Predictive modelling enabled us to accurate-




The BPS was initiated in 1990 on the west coast of Finland to
identify genetic factors contributing to type 2 diabetes, and
includes a cohort of 2770 non-diabetic individuals followed
for 10 years (median 7.7 years), 150 of whom developed type
2 diabetes [16]. A subpopulation of this cohort comprising
543 participants, whose fasting serum samples were available
for metabolomics analyses, was used in the current study. This
subpopulation thus included 146 participants who had
progressed to type 2 diabetes by the end of the follow-up
period, and 397 individuals randomly selected from those
who did not progress to type 2 diabetes, such that sex is bal-
anced. The ethics committee of the Helsinki University
Hospital approved the study protocols. All individuals gave
their informed consent to participation in the study.
Fasting serum samples collected at baseline were used for
metabolomic profiling. Sex, age, BMI, fasting glucose, fasting
insulin, family history of type 2 diabetes, waist circumference,
systolic BP (SBP), diastolic BP (DBP), total blood cholesterol,
HDL-cholesterol and triacylglycerols were recorded at base-
line. The level of physical activity, use of antihypertensive
medication (i.e. diuretics, beta blockers, calcium blockers,
ACE inhibitors, angiotensin II receptor type 2 receptor inhibi-
tors or other BP medication) and incidence of cardiovascular
disease (CVD) during the follow-up period were also recorded.
Glucose values measured using an OGTT at the end of the
follow-up period were used to define whether an individual
had progressed to type 2 diabetes (termed ‘progressors’) or
remained non-diabetic (termed ‘non-progressors’).
For replication of our results, we used untargeted metabo-
lomics data from fasting plasma samples of 1044 participants
in the DESIR (Data from an Epidemiological Study on the
Insulin Resistance Syndrome) study [10] from central western
France, of whom 231 progressed to type 2 diabetes during a
9 year follow-up period (electronic supplementary material
[ESM] Table 1). The ethics committee for the Protection of
Subjects for Biomedical Research of Bicêtre Hospital, France,
approved the study protocols. All individuals gave written
informed consent to their participation in the study.
Metabolomics
Samples were prepared using a single-extraction method.
Global untargeted metabolomics was performed using three
platforms (ultra-HPLC [UHPLC]-MS in electrospray
ionisation-positive and -negative modes, and GC-MS in
electrospray ionisation-positive mode) to semi-quantitatively
measure a diverse set of 542 serum metabolites. Targeted
metabolomics was performed using an isotope-dilution
UHPLC-MS/MS assay for the absolute quantification of 26
metabolites. Metabolites were identified by automated spec-
tral comparison with a standard library and missing values
were imputed using minimum non-missing measurement
[14, 17]. See ESM Methods for further details. The targeted
and untargeted metabolomics data were further standardised
to zero mean and unit variance per metabolite, and combined
into a single data matrix containing 568 metabolite measure-
ments from 543 samples. The DESIR validation data were
similarly acquired [10].
Statistical analysis
Fisher’s exact test was used to compare sex, family history,
physical activity, use of antihypertensive medication and the
presence of CVD between progressors and non-progressors,
while Welch’s two-sample t test was used to compare age,
BMI, fasting glucose, fasting insulin, waist size, SBP, DBP,
cholesterol, HDL-cholesterol and triacylglycerols. Individuals
with missing measurements for any of the clinical factors were
excluded from all of the analyses involving that particular
factor.
The statistical association of each metabolite with type 2
diabetes risk was assessed using logistic regression, using
progression to type 2 diabetes as the binary response variable
and the metabolite as the independent variable. ORs and cor-
responding significance levels (p value) were calculated from
the logistic regression. Q values were calculated to control for
the false discovery rate (FDR) [18]. Results at q < 0.05 were
considered significant. For each significant metabolite, to as-
sess whether its association with progression to type 2 diabe-
tes was independent of the clinical risk factors, we performed
multivariable logistic regression using the clinical covariates
as additional variables.
Predictive modelling
We used machine learning to build predictive models for fu-
ture type 2 diabetes risk and to find the most predictive bio-
marker combinations. In contrast to univariate statistical
analysis, predictive modelling uses the joint distribution of
the metabolic features to build multivariate models, while
employing model regularisation to prevent model overfitting
and to enable generalisation to new individuals. Regularised
least-squares (RLS) regression for binary risk classification
was used to build the metabolome-wide predictive model.
To select a minimal set of predictive metabolites, we used an
efficient greedy feature-selection approach for RLS
(GreedyRLS) [19].
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To carefully assess the predictive performance of the RLS
models beyond training data, we designed a repeated nested
stratified cross-validation approach (ESM Fig. 1) [20]. Ten
folds of outer cross-validation nested over ten folds of inner
cross-validation were repeated 100 times, with stratified fold
splitting to balance the numbers of progressors and non-
progressors across the folds. The outer cross-validation esti-
mated the prediction performance of the model, while the
inner cross-validation selected the regularisation parameter
and the linear coefficients. When applying GreedyRLS, we
used the regularisation parameter selected in the outer cross-
validation and the entire training data to determine the selected
features. Repetition of the nested cross-validation ensured that
the estimated prediction performance and the selected features
were not due to any single random fold-split in the outer cross-
validation. We reported the union of feature sets selected in
100 repetitions as the final biomarker panel.
Receiver operating characteristic (ROC) curves were also
derived based on the repeated nested cross-validation. The
mean of the AUC values was calculated from 100 ROC curves
and the 95% CI for the AUC was calculated as 2.5th and
97.5th percentile values. DeLong’s test for correlated ROC
curves was used to assess the pairwise differences between
competing models [21]. The DESIR validation data were also
predicted using model parameters obtained in 100 repeats and
averaged to calculate the ROC curve. The 95% CI of the
validation AUC was calculated using DeLong’s method
[21]. R packages ROCR [22] and pROC [23] were used for
ROC curve analyses.
We used integrated discrimination improvement (IDI) to
evaluate whether metabolites improved type 2 diabetes risk
prediction when combined with clinical risk factors [24]. To
calculate IDI, the RLS-based risk scores were converted into
risk probabilities by scaling with SD and applying logit trans-
formation. The discrimination slope (DS) of a model provides
a measure of its discriminative ability, similar to AUC. DS
was calculated as the difference in the mean risk probability
between progressors and non-progressors. IDI measures the
improvement obtained by adding new predictors and was cal-
culated as the difference in DS between models with and
without the new predictors, and expressed as percentage im-
provement obtained in DS [24]. IDI is equivalent to the inte-
gration of the net reclassification improvement over all cut-
offs for the risk probability.
Results
We performed comprehensive metabolomics experiments and
predictive modelling in 543 individuals from the BPS, includ-
ing 146 progressors to type 2 diabetes during a 10 year follow-
up period. The progressors and non-progressors were bal-
anced for sex (Table 1). All individuals had normal glucose
and insulin levels, but borderline-high cholesterol at the be-
ginning of the study. Progressors were older and had higher
BMI, fasting glucose and fasting insulin levels, waist size,
SBP, DBP, and triacylglycerols than non-progressors, while
HDL-cholesterol showed the opposite trend and total choles-
terol showed no difference (Table 1).
Targeted metabolomics measured 26 metabolites and
untargeted metabolomics detected 542 distinct metabolites
(316 identified and 226 unidentified) in the serum samples.
Metabolon (Durham, NC, USA) identifiers are used to refer to
the unknown metabolites (e.g. X-13435).
Individual metabolites are associated with type 2 diabetes
risk
Statistical analysis with logistic regression found that nine out
of 568 serum metabolites were negatively associated and 25
metabolites were positively associated with progression to
type 2 diabetes, after controlling for FDR (q < 0.05). All of
these metabolites were associated with progression to type 2
diabetes independent of fasting glucose levels at baseline,
physical activity and the future incidence of CVD (ESM
Fig. 2a, b). Sixteen of the metabolite associations were signif-
icant even after accounting for risk factors such as age, sex,
BMI, family history and fasting insulin (Fig. 1, Table 2) or
glucose (ESM Fig. 2a, b) level at baseline.
Reduced levels of glutamine, histidine, α-tocopherol and
the (E,E)-isomer of bilirubin at baseline were associated with
an increased risk of type 2 diabetes, independent of the risk
factors considered. Increased levels of glutamate, α-HB, va-
line, isoleucine, trehalose and several unknown metabolites
were associated with progression to type 2 diabetes indepen-
dent of the risk factors (Fig. 1).
The entire metabolomic profile predicts future
progression to type 2 diabetes
We tested how accurately the metabolome could predict pro-
gression to type 2 diabetes by applying a binary classification
based on RLS regression. The entire metabolomic profile
consisting of 568 serum metabolites predicted progression to
type 2 diabetes with an AUC of 0.77 (Fig. 2a). The reference,
clinical-only model using RLS regression with only the clin-
ical risk factors of sex, age, BMI, fasting insulin level and
family history predicted type 2 diabetes with an AUC of
0.68. The difference in the predictive performance between
the metabolomics-only and the clinical-only models was sta-
tistically significant (p = 0.0009, DeLong’s test). Finally, we
combined the clinical risk factors and the metabolomic profile
within a joint RLS predictive model. It predicted progression
to type 2 diabetes with an AUC of 0.76, a similar accuracy as
the metabolomics-only model (p = 0.23), but significantly
better than the clinical-only model (p = 0.005). The clinical-
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Table 1 Clinical characteristics
of individuals from the BPS used
in this study, for training predic-
tive models
Variable Total population Non-progressors Progressors p value
n 543 397 146
Sex
Male 274 200 74 1
Female 269 197 72
Age (years) 49.33 ± 0.59 48.22 ± 0.72 52.34 ± 0.99 0.00089
BMI (kg/m2) 26.59 ± 0.18 25.91 ± 0.19 28.46 ± 0.37 4.5 × 10−9
Waist circumference (cm) 90.34 ± 0.54 88.19 ± 0.59 96.15 ± 1.04 2.2 × 10−10
Fasting glucose (mmol/l) 5.68 ± 0.03 5.60 ± 0.03 5.90 ± 0.05 8.0 × 10−7
Fasting insulin (pmol/l) 44.33 ± 1.61 38.85 ± 1.26 59.34 ± 4.71 4.4 × 10−5
SBP (mmHg) 132 ± 0.84 129.47 ± 0.95 138.87 ± 1.60 9.6 × 10−7
DBP (mmHg) 80.11 ± 0.47 78.70 ± 0.55 83.94 ± 0.86 5.2 × 10−7
Total cholesterol (mmol/l) 5.71 ± 0.05 5.68 ± 0.07 5.81 ± 0.09 0.21
HDL-cholesterol (mmol/l) 1.33 ± 0.01 1.35 ± 0.01 1.27 ± 0.03 0.02
Triacylglycerols (mmol/l) 1.44 ± 0.04 1.34 ± 0.04 1.69 ± 0.08 0.00014
Family history of type 2 diabetes
No 30 27 3 0.01
Yes 289 190 99
Data missing 224 180 44
Future CVD
No 419 305 114 1
Yes 124 92 32
Physical activity
Low 18 12 6 0.07
Medium 315 222 93
High 184 146 38
Data missing 26 17 9
Hypertension medication
No 275 214 61 1
Yes 60 41 19
Data missing 208 142 66
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Fig. 1 Metabolites associated
with progression to type 2
diabetes at FDR q < 0.05. The
figure shows conditional ORs,
accounting for the risk factors
age, sex, BMI, fasting insulin
level and family history at
baseline. Error bars indicate the
95% CI. Metabolites with
quantitative data are labelled with
(Q) to differentiate them from
those with semi-quantitative data.
*p < 0.05, **p < 0.01,
***p < 0.001
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only model resulted in a DS of 0.12. The combined model
increased the DS to 0.19, resulting in an IDI of 58% (i.e. 58%
improvement in DS) (Fig. 2c, d).
As the fasting glucose level at baseline is a known risk
factor for type 2 diabetes, we added this into the clinical model
as an additional covariate. Although adding glucose improved
the clinical-only model (AUC = 0.70, DS = 0.14), the com-
bined model showed significantly better performance
(p = 0.023, IDI = 36%; ESM Fig. 3).
An additional clinical reference model that added fasting
glucose, total cholesterol, HDL-cholesterol, triacylglycerols,
SBP, DBP andwaist circumference improved the clinical-only
model (AUC = 0.71, DS = 0.15), although the combined
model again remained significantly better (p = 0.04,
IDI = 33%, ESM Fig. 4).
Specific metabolic biomarkers predict future progression
to type 2 diabetes
To better interpret the predictive ability of the metabolome, we
sought to identify the key metabolite features required for
optimal prediction accuracy by applying GreedyRLS. In order
to find the number of features required for optimal prediction
performance, we evaluated GreedyRLS by varying the model
size from one to 20 features, and thus determined that five
metabolites were sufficient for the maximal AUC (ESM
Fig. 5).
The five-metabolite signatures selected during 100 repeti-
tions of GreedyRLS predicted type 2 diabetes with an average
AUC of 0.75 (Fig. 2b), showing higher predictive accuracy
than the reference clinical-only model (AUC= 0.68), although
the difference was not significant (p = 0.18). However, com-
bining the panel of all selected metabolite features with clin-
ical variables led to the highest predictive performance
(AUC = 0.78; see also ESM Results), showing significant
improvement over the clinical-only model (p = 0.00019;
DS = 0.2, IDI = 66.7%; Fig. 2c, e) as well as over the
metabolite-only model (p = 0.0004). Combining the selected
metabolites also significantly improved performance over the
additional clinical models, namely the model that contained
fasting glucose (p = 0.0016, IDI = 43%, ESM Fig. 3) and the
model that contained fasting glucose, total cholesterol, HDL-
cholesterol, triacylglycerols, SBP, DBP and waist size
(p = 0.0025, IDI = 40%, ESM Fig. 4) as additional clinical
covariates.
Among the biomarker panel, formed as the union of the
metabolic predictors selected during 100 repetitions of
GreedyRLS, three metabolites were associated with decreased
type 2 diabetes risk: α-tocopherol, bradykinin (BK) hydroxy-
proline ([Hyp3]-BK) and X-13435; and four were associated
with increased risk: α-HB, glucose, mannose and X-12063
(Fig. 3, Table 3). These metabolic predictors, except
X-13435, were associated with progression to type 2 diabetes,
independent of traditional risk factors as well as of physical
activity, use of hypertension medication and future incidence
of CVD (ESM Fig. 2c). Mannose showed high correlation
with fasting glucose, while X-12063, [Hyp3]-BK and α-HB
showed low but statistically significant correlation (ESM
Table 2).
The metabolomics data from the DESIR study included
semi-quantitative measurements of four of our seven metabol-
ic markers, namely glucose, mannose, α-HB and α-
tocopherol [10]. We used these metabolites and the clinical
covariates of sex, age, BMI, family history and fasting insulin
measured in the DESIR study samples to predict the progres-
sion of these individuals to type 2 diabetes (Fig. 4). The val-
idation AUC values for the clinical-only and combined
models were 0.76 and 0.84, respectively, and the selected
metabolic markers significantly improved the prediction per-
formance over the clinical-only model (p = 5.4 × 10−7;
IDI = 31.6%).
Discussion
Using comprehensive metabolomics profiling, we have iden-
tified a novel multivariate panel of metabolic markers
consisting of glucose, mannose, α-HB, α-tocopherol,
Table 2 Metabolites associated with progression to type 2 diabetes at
FDR q < 0.05
Metabolite OR (95% CI)a p valuea
Glucose 1.83 (1.40, 2.44) 1.7 × 10−5
Mannose 1.76 (1.35, 2.33) 4.3 × 10−5
X-16071 (RI: 3616, M: 146.2) 1.65 (1.25, 2.23) 0.00066
α-HB (Q)b 1.60 (1.23, 2.13) 0.00077
X-13537 (RI: 5292, M: 295.3) 1.58 (1.21, 2.09) 0.0011
Isoleucine 1.46 (1.08, 2.02) 0.017
X-13452 (RI: 3606, M: 192.2) 1.44 (1.11, 1.90) 0.0079
Valine 1.40 (1.04, 1.90) 0.026
Glutamate (Q)b 1.38 (1.04, 1.85) 0.029
X-12844 (RI: 4168, M: 539.3) 1.35 (1.03, 1.78) 0.032
X-12802 (RI: 2731, M: 318.2) 1.30 (1.03, 1.67) 0.029
Trehalose 1.29 (1.02, 1.65) 0.036
Histidine 0.68 (0.52, 0.89) 0.0054
Bilirubin (E,E) 0.62 (0.44, 0.84) 0.0033
Glutamine 0.58 (0.39, 0.82) 0.0046
α-Tocopherol 0.53 (0.34, 0.77) 0.0023
a Conditional ORs (accounting for the risk factors of age, sex, BMI,
fasting insulin level and family history of type 2 diabetes), 95% CIs and
p values were calculated using multivariate logistic regression
bMetabolites with quantitative data are labelled with (Q) to differentiate
them from those with semi-quantitative data
M, mass to charge ratio of the peak; RI, retention index
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[Hyp3]-BK, X-12063 and X-13435, whose concentrations in
fasting serum samples predicted future progression to type 2
diabetes in an otherwise healthy, normoglycaemic population,
years before the onset of type 2 diabetes (Fig. 3, Table 3).
These metabolic markers significantly improved the predic-
tion of progression towards type 2 diabetes, showing the
added value of screening metabolites along with clinical risk
factors.
Statistical association testing and machine learning-based
predictive modelling identified metabolic changes that pre-
ceded type 2 diabetes. Statistical tests identified 34 significant
metabolites, yet multivariate predictive models required only
five metabolites for the optimal prediction of progression to
type 2 diabetes. While the metabolite features identified using
both approaches are well supported in type 2 diabetes litera-
ture, our novel contribution was in systematically assessing
the predictive performance of the biomarker panel in type 2
diabetes risk prediction.
Statistical associations
Histidine, glutamine and the (E,E)-isomer of bilirubin were
negatively associated with type 2 diabetes risk independent
of clinical risk factors (ESM Fig. 2b). Histidine-mediated sup-
pression of hepatic glucose production has previously been
suggested as a potential target for the treatment of type 2
diabetes [25]. In a double-blind placebo-controlled trial in
participants with type 2 diabetes, glutamine supplementation
yielded positive results [26]. Bilirubin has previously been
reported to be negatively correlated with progression to dia-
betic nephropathy in individuals with type 2 diabetes [27, 28].
Glutamate and trehalose were positively associated with
type 2 diabetes risk independent of clinical risk factors
(Table 2, Fig. 1, ESM Fig. 2a). Plasma glutamate levels are
known to be elevated in several diseases characterised by
chronic oxidative stress and inflammation. Furthermore,























































































































































Fig. 2 ROC curves of the predictive models based on (a) the entire me-
tabolome (i.e. set of 568 metabolites) and (b) selected metabolic markers:
glucose, mannose, α-HB, X-12063, α-tocopherol, [Hyp3]-BK and
X-13435. The mean AUC value obtained with the clinical-only model
was 0.68 (95% CI 0.48, 0.86) (red dashed line). (a) The metabolome-only
model (solid blue line) had ameanAUC of 0.77 (95%CI 0.62, 0.90), while
the combined model (green dashed-dot line) had a mean AUC of 0.76
(95% CI 0.59, 0.92). (b) The selected metabolic markers (solid blue line)
had a mean AUC of 0.75 (95% CI 0.59, 0.89), while the combined model
(dashed-dot line) had ameanAUC of 0.78 (95%CI 0.61, 0.92). DS plots of
(c) the clinical-only model (DS = 0.12), (d) the combined model with
clinical covariates and 568 metabolites (DS = 0.19) and (e) the combined
model with clinical covariates and metabolic markers (DS = 0.20). White
boxes in the DS plots show the predicted probabilities for progressors (P)
and non-progressors (NP), and the black squares inside the boxes show the
mean probabilities per group. The IDI was 58%with the entiremetabolome
and 66.7% with the selected markers
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or indirectly contribute to the progressive loss of beta cells in
both type 1 and type 2 diabetes [29]. Although trehalose is
widely regarded as a safe food ingredient even for individuals
with diabetes, trehalose was associated with increased type 2
diabetes risk in this study. Similar results have been previously
reported in an African-American population [30].
Predictive modelling
The machine learning model based on the entire metabolome
accurately predicted the future incidence of type 2 diabetes. To
derive a more interpretable model, we performed feature
selection and identified the most predictive metabolic markers
(Fig. 3, Table 3). Combining clinical variables with the select-
ed markers significantly improved the predictive performance
over the reference model with clinical variables alone, and led
to the model with the highest predictive performance. Even
after excluding glucose, the combined predictive model
outperformed the clinical reference model that contained
fasting glucose (p = 0.0066, ESM Fig. 6), showing that the
predictive performance of the marker panel was not solely due
to glucose. Excluding glucose as well as mannose from the
marker panel resulted in a reasonable combined predictive
model (AUC = 0.75) that outperformed the reference model
(p = 0.04), further supporting the value of our novel markers.
Among the biomarkers identified using feature selection
(Fig. 3, Table 3), three showed negative associations and four
showed positive associations with type 2 diabetes risk. The neg-
atively associated markers were [Hyp3]-BK, α-tocopherol and
X-13435 and, to the best of our knowledge, this is the first
metabolomics study revealing the value of these markers in
predicting type 2 diabetes risk. The positively associated
markers were glucose, mannose, α-HB and X-12063.
Mechanisms by which mannose is associated with an increased
risk of type 2 diabetes independently of glucose have previously
been suggested [31]. Identifying the unknownmarkers X-13435
and X-12063, although non-trivial, may reveal potentially novel
pathways associated with progression to type 2 diabetes.
BK BK is a peptide that causes vasodilation associated with
BP lowering and protection from CVD [32]. [Hyp3]-BK is a
a
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Fig. 3 Metabolic markers
identified based on 100
repetitions of GreedyRLS. (a)
Boxes show the spread of
regression coefficients of the
selected features over the
repetitions. The sign of a
coefficient indicates whether the
marker increased or decreased the
risk of type 2 diabetes, and the
magnitude indicates the
predictive strength of the marker.
(b) Univariate association of
metabolic markers with
progression to type 2 diabetes
shown as ORs (95% CI).
**p < 0.01, ***p < 0.0001
Table 3 Statistical association of multivariate predictive markers with
progression to type 2 diabetes
Metabolite OR (95% CI)a p valuea
Glucose 2.18 (1.77, 2.71) 7.9 × 10−13
Mannose 2.05 (1.67, 2.54) 1.5 × 10−11
X-12063 (RI: 4822, M: 427.2) 1.86 (1.53, 2.27) 5.1 × 10−10
α-HB (Q)b 1.57 (1.3, 1.92) 6.4 × 10−6
X-13435 (RI: 4640, M: 314.3) 0.82 (0.66, 1.00) 0.058
α-Tocopherol 0.62 (0.46, 0.81) 0.0011
[Hyp3]-BK 0.55 (0.43, 0.7) 2.3 × 10−6
a ORs, 95% CIs and p values were calculated using logistic regression
bMetabolites with quantitative data are labelled with (Q) to differentiate
them from those with semi-quantitative data
M, mass to charge ratio of the peak; RI, retention index
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BK analogue in which the third amino acid, proline, is hy-
droxylated. In this study, [Hyp3]-BK was negatively associat-
ed with type 2 diabetes risk independent of CVD risk
(p = 2.2 × 10−6). However, as BK was elevated in progressors,
showing an opposite trend (data not shown), we additionally
tested the association of the total amount of BK and [Hyp3]-
BK with progression. The total BK level was also negatively
associated with progression to type 2 diabetes (p = 0.004).
Diabetes decreases the activity of the kallikrein–kinin system
by reducing the synthesis of plasma prekallikrein and hence
BK, resulting in endothelial dysfunction [33, 34]. The current
study revealed reduced levels of total BK far before the onset
of type 2 diabetes, indicating a potential early role for the
kallikrein–kinin system or oxidative stress and DNA damage
associated with reduced BK in progression to type 2 diabetes.
Interestingly, physical exercise improves glucose uptake by
skeletal muscle resulting in improved insulin sensitivity, an
effect that is partially mediated by an increased BK concen-
tration, suggesting a mechanism by which physical exercise
would contribute to the prediction of type 2 diabetes [33,
35–37]. [Hyp3]-BK was associated with type 2 diabetes risk
independently of physical activity, antihypertensive medica-
tion and CVD (ESM Fig. 2c).
α-Tocopherol A reduction in α-tocopherol, the most biolog-
ically active form of vitamin E in humans, was seen in
progressors, and it was selected in the biomarker panel.
Although observational studies have previously indicated a
protective effect of vitamin E supplementation on glycaemic
control in type 2 diabetes, randomised controlled trials have
not confirmed the effect [38–40].
The unknowns (X-13435 and X-12063) The unknown me-
tabolite X-12063 showed a strong association with progres-
sion towards type 2 diabetes, and was selected in the biomark-
er panel (Fig. 3). Although its identity is currently unknown,
this metabolite has previously been noted to be significantly
associated with insulin resistance and glucose intolerance
[14]. X-13435, which was not identified in earlier metabolo-
mics studies, did not show univariate statistical association,
but predicted type 2 diabetes risk jointly with the other
markers.
All of the metabolic markers were associated with progres-
sion to type 2 diabetes independently of fasting glucose (ESM
Fig. 2c). Except for X-13435, they were all associated with
progression to type 2 diabetes independently of CVD, physi-
cal activity and use of hypertension medication. While man-
nose was highly correlated with fasting glucose, [Hyp3]-BK
and X-12063 showed statistically significant yet low correla-
tions. Similarly, α-HB showed a relatively low correlation,
although statistically significant, with fasting glucose (ESM
Table 2).
Taken together, the statistical analysis and predictive
modelling identified a variety of known metabolic changes
associated with progression to type 2 diabetes (ESM Fig. 2).
In agreement with a recent meta-analysis [9], our study iden-
tified changes in BCAAs (valine and isoleucine), amino acids
(histidine, glutamine and glycine), sugars (glucose and man-
nose) and other metabolites (glutamate, α-HB and L-GPC).
Benchmarking of the predictive markers
According to our benchmarking results, our new biomarker






























































































Fig. 4 (a) ROC curves for the predictive models based on the metabolic
markers glucose, mannose, α-HB and α-tocopherol in the DESIR study
as an independent validation of the marker panel. The clinical-only model
(red dotted line) included the clinical risk factors sex, age, BMI, fasting
insulin level and family history of type 2 diabetes, while the combined
model (green solid line) included the clinical risk factors and metabolic
markers. The mean AUC was 0.76 (95% CI 0.73, 0.80) for the clinical-
only model and 0.84 (95% CI 0.81, 0.87) for the combined model. The
combinedmodel showed a significant improvement over the clinical-only
model (p = 5.4 × 10−7). DS plots of (b) the clinical-only model
(DS = 0.19) and (c) the combined model (DS = 0.25). White boxes in
the DS plots show the predicted probabilities for progressors (P) and non-
progressors (NP), and the black squares inside the boxes show the mean
probabilities per group. The IDI obtained after adding the metabolic pre-
dictors to the clinical-only model was 31.6%
1748 Diabetologia (2017) 60:1740–1750
markers, namely α-HB and L-GPC [14, 15] and amino acids
[13]. α-HB was associated with increased insulin resistance
and glucose intolerance, whereas L-GPC was protective [14,
15]. Predictive modelling with α-HB and L-GPC revealed a
high predictive performance (AUC= 0.72; ESM Fig. 7), when
combined with clinical covariates.
BCAAs are associatedwith insulin resistance, and the com-
bination of isoleucine and the amino acids tyrosine and phe-
nylalanine has been reported to predict the risk of type 2 dia-
betes 12 years before disease onset [13]. Consistent with pre-
vious studies, joint modelling of isoleucine, tyrosine, phenyl-
alanine and clinical covariates showed high predictive perfor-
mance (AUC = 0.71; ESM Fig. 7). As these amino acids are
consistently found in many studies of prediabetes (i.e. im-
paired glucose tolerance, impaired fasting glucose, insulin re-
sistance or impaired insulin sensitivity) and type 2 diabetes
[9], they may have high potential for routine use as predictive
biomarkers, and further translational research is needed to
facilitate their clinical use.
Limitations of the study
Distinct predictive signatures may be discovered in different
studies due to differences in the metabolites measured, or dif-
ferences in the genetic and environmental background of the
study population. The relatively large overlap of our biomark-
er panel with known markers of type 2 diabetes, however,
suggests that our results are robust and stable. Replication of
our findings in the DESIR data also shows that the predictive
model trained using Finnish individuals generalised to inde-
pendent French individuals, despite the potential variability
due to the demographic difference.
α-HB was quantitatively measured in the BPS dataset, but
using an untargeted platform in the DESIR dataset. Moreover,
three of the metabolic markers, [Hyp3]-BK, X-12063 and
X-13435, were not measured in the DESIR study. Despite
these differences, we confirmed the high predictive perfor-
mance and added predictive value of the selected metabolic
markers in the independent study.
Conclusions
Progressors and non-progressors have different metabolic pro-
files years before they develop overt type 2 diabetes. In this
study, a combination of known markers such as glucose, man-
nose and α-HB, and novel markers such as α-tocopherol,
[Hyp3]-BK, X-12063 and X-13435, was found to accurately
predict progression to type 2 diabetes. Interestingly, the nega-
tive association of [Hyp3]-BK with progression to type 2 di-
abetes highlights a possible mechanism by which interven-
tions such as exercise could contribute to the prevention of
type 2 diabetes.
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